First Cellvizio Order Placed by UGAP, France’s Largest Hospital Purchasing Group, for Avignon’s Hospital Complex

31 Mar, 2016, 11:45 ET from Mauna Kea Technologies

PARIS, March 31,2016 /PRNewswire/ --

Key stage in the development of the French market, with access to Innovation supported by UGAP
Mauna Kea Technologies won UGAP's innovation competitive bidding in late 2015

Mauna Kea Technologies (Euronext: MKEA, FR0010609263, PEA-PME/PMI), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, is announcing that it has received the first Cellvizio order from Union des Groupements d'Achat Public (UGAP) for Avignon's hospital complex just a few weeks after winning the "Innovations" competitive bidding launched by France's largest hospital purchasing group in November 2015.

"This represents a key stage in the development of the French market, our domestic market. Despite the public authorities' failure to address the near-impossibility for innovative medical devices to gain access to the French market, Avignon's hospital complex is the 29th French healthcare facility to acquire a Cellvizio. Working together with UGAP, we successfully made it much easier for practitioners keen to provide their patients with a higher standard of service to obtain our technology", stated Sacha Loiseau, Founder and Chief Executive Officer of Mauna Kea Technologies.

The gastro-hepato-enterology and digestive endoscopy department at the Avignon hospital complex directed by Dr. Jean-Pierre Arpurt, will rapidly be able to provide its patients with cystic lesions of the pancreas, biliary tract diseases or those at risk of digestive and biliary tract cancer with improved care and avoid repeated and even unnecessary procedures.

In 2015, UGAP arranged its annual competitive bidding procedure for "disruptive" medical innovations, with the "degree of innovation" accounting for 20% of the total score in the analysis of bids, to provide healthcare facilities with ongoing and straightforward access to the most advanced medical innovations. Mauna Kea Technologies was one of the four innovative businesses chosen in this first selection.

"We are very proud to provide French hospitals with easier access to the best innovations, which have received worldwide acclaim, such as Mauna Kea Technologies' Cellvizio", stated Sébastien Taupiac, UGAP's Director of Innovation.

About Mauna Kea Technologies 
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com   

Mauna Kea Technologies
Investors relations US
Sebastien Cadet
Global Marketing Director and OEM Leader
investors@maunakeatech.com

France and Europe
NewCap - Investor Relations | Strategic Communication
Florent Alba/Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr

This is a disclosure announcement from PR Newswire.

SOURCE Mauna Kea Technologies